Table S1.
Incidence of adverse events (in ≥2% of patients in any group) according to treatment received and age group
| Patients <65 years
|
Patients ≥65 years
|
|||
|---|---|---|---|---|
| Placebo
|
Duloxetine
|
Placebo
|
Duloxetine
|
|
| (n=68) | (n=72) | (n=108) | (n=106) | |
| Overall | 39 (57.4%) | 47 (65.3%) | 59 (54.6%) | 73 (68.9%) |
| Nasopharyngitis | 16 | 12 | 12 | 15 |
| Somnolence | 2 | 12 | 4 | 12 |
| Nausea | 1 | 9 | 0 | 9 |
| Constipation | 1 | 8 | 2 | 11 |
| Malaise | 1 | 6 | 1 | 6 |
| Decreased appetite | 1 | 6 | 0 | 3 |
| Headache | 4 | 1 | 1 | 0 |
| Dry mouth | 0 | 4 | 3 | 15 |
| Back pain | 3 | 1 | 5 | 0 |
| Diarrhea | 1 | 3 | 0 | 3 |
| Contusion | 2 | 1 | 5 | 8 |
| Abdominal discomfort | 2 | 1 | 2 | 1 |
| ALT increase | 0 | 0 | 1 | 8 |
| AST increase | 0 | 0 | 1 | 7 |
Notes: Values are presented as n (%) or n.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.